



EHA2023 abstracts

What's hot in MPN?

To help navigate the exciting content being presented at the EHA2023 Congress, the MPN Hub Steering Committee have provided their recommendations of the top abstracts to look for.



Click
the abstracts
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://mpn-hub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

Brought to you by SES



Scientific Education Support

Oral abstract sessions and poster presentations

Friday, June 9, 2023

Abstract	Type	Title	Presenter
S168	Oral presentation	<u>Pelabresib (CPI-0610) monotherapy in patients with high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study</u>	Francesco Passamonti
P1008	Poster presentation	<u>The telomerase inhibitor imetelstat differentially targets JAK2V617F- versus CALR-mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling</u>	Nicolas Chatain
P1027	Poster presentation	<u>Updated durability of response and safety in MANIFEST Arm 3: Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis</u>	Claire Harrison
P1032	Poster presentation	<u>Characteristics and clinical outcomes in patients with polycythemia vera receiving ruxolitinib after hydroxyurea: A longitudinal analysis from reveal</u>	Ruben Mesa
P1044	Poster presentation	<u>Reduction in red blood cell transfusion burden: A novel longitudinal time-dependent analysis in patients with transfusion-dependent myelofibrosis treated with momelotinib</u>	Claire Harrison
P1057	Poster presentation	<u>Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis</u>	Lucia Masarova
P1062	Poster presentation	<u>Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis</u>	Francesca Palandri

Oral abstract sessions and poster presentations

Saturday, June 10, 2023

Abstract	Type	Title	Presenter
S210	Oral presentation	<u>An open-label, global, phase 1b/2 study adding navtemadlin (NVTM) to ruxolitinib (RUX) in patients with primary or secondary myelofibrosis who have a suboptimal response to RUX</u>	John Mascarenhas
S211	Oral presentation	<u>Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis: Updated results and genomic characteristics</u>	Harry Gill
S212	Oral presentation	<u>A randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high risk myelofibrosis</u>	Yi Zhang
S213	Oral presentation	<u>BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis: Results from a phase 1/2 study</u>	Haifa Kathrin Al-Ali

Sunday, June 11, 2023

Abstract	Type	Title	Presenter
LB2710	Late breaking oral presentation	<u>Targeted therapy of uncontrolled erythrocytosis in polycythemia vera with the hepcidin mimetic, rusfertide: Blinded randomized withdrawal results of the REVIVE study</u>	Marina Kremyanskaya



Follow us on Twitter to keep up to date with the latest from the EHA2023 Congress.

@MPN_Hub

#EHA2023

mpn-hub.com